BioCentury | Oct 5, 2018
Company News

Janssen terminates licenses to Aduro cancer therapies

...and ADU-214 are live-attenuated, double-deleted Listeria monocytogenes -based immunotherapies. ADU-741 targets multiple undisclosed prostate-specific antigens; ADU-214...
...BioTech Inc. (NASDAQ:ADRO), Berkeley, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Cancer Sandi Wong ADU-214, JNJ-64041757 ADU-741...
BioCentury | Dec 1, 2016
Clinical News

CRS-207: Ph IIb resumed

...and a Phase I/II trial in ovarian cancer. Aduro’s other LADD-based candidates include ADU-623 , ADU-214...
...Endpoint: Overall survival (OS); safety and immune response Status: Phase IIb resumed Milestone: NA Jaime De Leon ADU-214 ADU-623 ADU-741 CRS-207 Aduro...
BioCentury | Nov 21, 2016
Clinical News

FDA lifts partial hold on Aduro's candidates

...of L. monocytogenes that expresses human mesothelin . Aduro’s other LADD-based candidates include ADU-623 , ADU-214...
...Phase I studies to treat various cancers. Aduro gained $0.05 to $14 on Monday. Jaime De Leon ADU-214 ADU-623 ADU-741 CRS-207 Aduro...
BioCentury | Oct 31, 2016
Clinical News

CRS-207: Phase IIb hold

...antigen 1B (NY-ESO-1; CTAG1B) and is in a Phase I trial to treat high-grade glioma; ADU-214...
...of Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) has exclusive, worldwide rights from Aduro to ADU-214...
BioCentury | Oct 24, 2016
Clinical News

Partial clinical hold for Aduro's Listeria candidates

...I/II trial in ovarian cancer. In addition to CRS-207, Aduro's LADD-based candidates include ADU-623 , ADU-214...
BioCentury | Jan 18, 2016
Clinical News

ADU-214: Phase I started

...Janssen Biotech Inc. unit began a 2-part, open-label, U.S. Phase I trial to evaluate IV ADU-214...
...metastatic NSCLC. The dose-escalation part 1 of the trial will evaluate 2 dose levels of ADU-214...
...Part 2 of the trial will enroll 30 additional patients to receive the dose of ADU-214...
Items per page:
1 - 6 of 6